<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03867370</url>
  </required_header>
  <id_info>
    <org_study_id>JS001-020-Ib-HCC</org_study_id>
    <nct_id>NCT03867370</nct_id>
  </id_info>
  <brief_title>Toripalimab or Placebo as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma</brief_title>
  <official_title>A Phase Ib/II, Open-Label, Single-Center, Single-Arm Study Evaluating the Efficacy and Safety of Toripalimab Injection (JS001) as a Neoadjuvant Therapy for Patients With Resectable Hepatocellular Carcinoma (HCC) or Intrahepatic Cholangiocarcinoma (ICC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Junshi Bioscience Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate efficacy and safety of Toripalimab Injection (JS001) as a
      Neoadjuvant Therapy in patients with Resectable Hepatocellular Carcinoma (HCC) or
      Intrahepatic Cholangiocarcinoma (ICC)
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">November 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 28, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological response rate</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>assessed using the percentage of the non-viable cancer cells (necrotized or fibrotized) out of the surface expression of the total tumor area, which is: 100% - viable cancer cells %. If there are a number of tumors, then the mean value of the tumor percentages will be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to operation</measure>
    <time_frame>Up to 8 months</time_frame>
    <description>Used for assessment of the feasibility of the neoadjuvant therapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Epatocellular Carcinoma, Intrahepatic Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A:TORIPALIMAB 240mg ,Q3W, up to 48 Weeks;</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TORIPALIMAB INJECTION(JS001 )</intervention_name>
    <description>During the neoadjuvant period, the patients will receive a single JS001 intravenous infusion of 480 mg . After the operation, the patients wil receive JS001 240 mg Q3W.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed by histopathological or cytological examination;

          2. The criteria for resectability is met

          3. Has at least one evaluable lesion according to the RECIST 1.1 standard and has not
             received local treatment

        Exclusion Criteria:

          1. Patients who previously received anti-programmed death receptor-1 (PD-1) antibody,
             anti-programmed death ligand-1 (PD-L1) antibody, anti-programmed death ligand-2
             (PD-L2) antibody or anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4)
             antibodies, including those who have participated in a JS001 clinical study;

          2. Patients who previously received any TACE, radiofrequency ablation and other liver
             cancer treatments;

          3. Patients with a history of gastroesophageal varices or active cardia ulcers associated
             with a high risk of bleeding;

          4. Patients who have upper gastrointestinal hemorrhage within 1 year;

          5. Patients known to have fibrous layer HCC, sarcomatoid HCC or mixed cholangiocarcinoma
             and HCC; Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jia Fan</last_name>
    <phone>+86 13601669720</phone>
    <email>fan.jia@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2019</study_first_posted>
  <last_update_submitted>October 21, 2019</last_update_submitted>
  <last_update_submitted_qc>October 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

